

Relationships With Industry

Name: **Shaun Goodman**
 Last updated: **November 1, 2025**

| Company/(Companies): | Period of Support | Name of Project | 1) A research grant or contract from this Company generates revenue for the University of Alberta | 2) A research grant or contract from this Company partially supports my research projects | 3) Educational activities or lectures for this Company generates revenue for the University of Alberta | | 4) Consulting or other services for this company generates personal income | | 5) I receive significant personal royalties from this Company | 6) I have equity in this Company | Comments |
|---|-------------------|--|---|---|--|--------------------------|--|-------------------------------------|---|----------------------------------|---|
| | | | | | <\$10K | >\$10K | <\$10K | >\$10K | | | |
| Canadian VIGOUR Centre (including support from CSL and Boehringer-Ingelheim) | 2010-present | AEGIS-2 (2016-present), EMPACT-MI (2020-present), OCEANIC-AF (2021-present), POSIBIL-6 (2022-present) trials | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Including quarterly stipend directed to the St. Michael's Physician's Association |
| Duke Clinical Research Institute (including support from Daiichi-Sankyo/American Regenent, CSL, and Boehringer-Ingelheim) | 2010-present | EMPACT-MI (2021-present) and HEART-FID (2019-2023) trials | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Including National Coordinator and DMC activities |
| Canadian Heart Research Centre and MD Primer | 1996-present | Multiple clinical trials, observational registries, and continuing professional development programs | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Including quarterly stipend directed to the St. Michael's Physician's Association (1996-2022) |
| New York University | 2012-present | ISCHEMIA/ISCHEMI | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| Heart & Stroke Foundation of Ontario/University of Toronto | 2011-2021 | Heart & Stroke/University of Toronto Polo Chair, Division of Cardiology, Department of Medicine | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Monthly stipend directed to the St. Michael's Physician's Association (2011-2021) |
| Mayo Clinic | 2012-2020 | TAILOR-PCI trial | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| HCor | 2015-2019 | TREAT trial | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Steering Committee Member |
| AstraZeneca | 2015-2019 | Canadian ACS Reflective II | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Principal Investigator |
| Bayer | 2017-2019 | CONNECT AF+PCI | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Principal Investigator |
| Bristol-Myers Squibb/Pfizer | 2019-2020 | CONNECT AF+PCI II | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Principal Investigator |
| Bayer | 2018-2019 | CONNECT CVD | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Principal Investigator |
| Sanofi/Regeneron | 2012-2019 | ODYSSEY Outcomes trial | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Executive Steering Committee stipend |
| AstraZeneca | 2013-2020 | TIGRIS study | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Executive Steering/Publication Committee stipend |
| Novo-Nordisk | 2019-present | SOUL and FLOW trials | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Data Monitoring Committee member |
| Daiichi-Sankyo/American Regent | 2017-2023 | HEART-FID trial | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Data Monitoring Committee member |
| University Court of the University of Edinburgh | 2014-present | ACS Risk Working Group Canadian study | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| Ferring Pharmaceuticals | 2015-2021 | PRONOUNCE trial | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Executive Steering Committee member |
| Bristol-Myers Squibb/Pfizer | 2015-2019 | AUGUSTUS trial | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Executive Steering Committee member |
| Bristol-Myers Squibb/Pfizer | 2016-2019 | OPTIMAL AF | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Principal Investigator |

Relationships With Industry

Name: **Shaun Goodman**
 Last updated: **November 1, 2025**

| Company/(Companies): | Period of Support | Name of Project | 1) A research grant or contract from this Company generates revenue for the University of Alberta | 2) A research grant or contract from this Company partially supports my research projects | 3) Educational activities or lectures for this Company generates revenue for the University of Alberta | | 4) Consulting or other services for this company generates personal income | | 5) I receive significant personal royalties from this Company | 6) I have equity in this Company | Comments |
|--|-------------------|---|---|---|--|--------------------------|--|-------------------------------------|---|----------------------------------|-------------------------------------|
| | | | | | <\$10K | >\$10K | <\$10K | >\$10K | | | |
| Amgen Pharmaceuticals | 2015-2020 | GOAL and GOAL-2 registries | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Steering Committee member |
| Amgen Pharmaceuticals | 2019-2020 | CV MOBIUS | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Executive Steering Committee member |
| CSL Behring (through PERFUSE Research Institute) | 2016-present | AEGIS-II | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Executive Steering Committee member |
| Esperion (through Cleveland Clinic Coordinating Center for Clinical Research [C5]) | 2018-2023 | CLEAR OUTCOMES | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Steering Committee member |
| Boehringer-Ingelheim | 2020-present | EMPACT-MI | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Steering Committee member |
| Bayer | 2020-2023 | TRANSECT AF | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Principal Investigator |
| Novartis | 2020-2023 | HF-iDOC | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Study Chair |
| Bayer | 2021-present | OCEANIC-AF | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Executive Steering Committee member |
| CSL Behring (through the Duke Clinical Research Institute [DCRI]) | 2022-present | POSIBIL-6 | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Canadian site operations |
| TIMI Study Group (Brigham Health; through Anthos Therapeutics) | 2020-present | AZALEA-TIMI 71 (2020-present) and LILAC (2022-present) trials | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Steering Committee member |
| CYTE | 2022-present | GARDENIA Registry (2022-present) | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Steering Committee member |
| Idorsia | 2021-present | SOS-AMI (2021-present) | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Steering Committee member |
| Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, Eli Lilly, Ferring Pharmaceuticals, HLS Therapeutics, JAMP Pharma, Merck, Novartis, PendoPharm/Pharmascience, Pfizer, Regeneron, Sanofi, Servier, Valeo Pharma | 2016-present | Consulting/Advisory Boards/Rounds/Slide set development | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| | | | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| | | | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| | | | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |

Monetary amounts are on an annual basis.